# Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy

> **NCT03201913** · PHASE1 · COMPLETED · sponsor: **TTC Oncology, LLC** · enrollment: 15 (actual)

## Conditions studied

- Metastatic ER+ Breast Cancer

## Interventions

- **DRUG:** TTC-352

## Key facts

- **NCT ID:** NCT03201913
- **Lead sponsor:** TTC Oncology, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-11
- **Primary completion:** 2019-12-31
- **Final completion:** 2020-04-30
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2020-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03201913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03201913, "Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03201913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*